1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Anti GM-CSF Antibody -Pipeline Insights, 2016

Anti GM-CSF Antibody -Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “Anti GM-CSF Antibody-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Anti GM-CSF Antibody. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti GM-CSF Antibody. DelveInsight’s Report also assesses the Anti GM-CSF Antibody therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Anti GM-CSF Antibody
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Anti GM-CSF Antibody pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Anti GM-CSF Antibody and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Anti GM-CSF Antibody -Pipeline Insights, 2016

- Anti GM-CSF Antibody Overview
- Anti GM-CSF Antibody Disease Associated
- Anti GM-CSF Antibody Pipeline Therapeutics
- Anti GM-CSF Antibody Therapeutics under Development by Companies
- Anti GM-CSF Antibody Filed and Phase III Products
- Comparative Analysis
- Anti GM-CSF Antibody Phase II Products
- Comparative Analysis
- Anti GM-CSF Antibody Phase I and IND Filed Products
- Comparative Analysis
- Anti GM-CSF Antibody Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Anti GM-CSF Antibody - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anti GM-CSF Antibody - Discontinued Products
- Anti GM-CSF Antibody - Dormant Products
- Companies Involved in Therapeutics Development for Anti GM-CSF Antibody
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Anti GM-CSF Antibody by Therapy Area, 2016
- Number of Products under Development for Anti GM-CSF Antibody, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Anti GM-CSF Antibody Assessment by Monotherapy Products
- Anti GM-CSF Antibody Assessment by Combination Products
- Anti GM-CSF Antibody Assessment by Route of Administration
- Anti GM-CSF Antibody Assessment by Stage and Route of Administration
- Anti GM-CSF Antibody Assessment by Molecule Type
- Anti GM-CSF Antibody Assessment by Stage and Molecule Type
- Anti GM-CSF Antibody Therapeutics - Discontinued Products
- Anti GM-CSF Antibody Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Anti GM-CSF Antibody by Therapy Area, 2016
- Number of Products under Development for Anti GM-CSF Antibody, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Anti GM-CSF Antibody Assessment by Monotherapy Products
- Anti GM-CSF Antibody Assessment by Combination Products
- Anti GM-CSF Antibody Assessment by Route of Administration
- Anti GM-CSF Antibody Assessment by Stage and Route of Administration
- Anti GM-CSF Antibody Assessment by Molecule Type
- Anti GM-CSF Antibody Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
GM-CSF Inhibitors -Pipeline Insights, 2016

GM-CSF Inhibitors -Pipeline Insights, 2016

  • $ 1250
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “GM-CSF Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the GM-CSF Inhibitors. The DelveInsight’s ...

Cancer Immunotherapy Market by Type, Application, End User - Global Forecast to 2021

Cancer Immunotherapy Market by Type, Application, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.